Table 8. Pyrrolopyrimidinones and pyrazoles from Novartis.

Compd	R	IC50a (nM)	EC50b (nM)
60	F	200	350
61		51	110
62		2000
63	p-OMe	84
64c		82	5300 (4100)
65c		61	2500 (2000)

^aExpressed as the inhibition of MK2 activity toward a peptide substrate.

^bExpressed as the ability to inhibit TNFα production in hPBMC cells stimulated with both LPS and IFNγ, and to inhibit Hsp27 phosphorylation in anisomycin-stimulated THP-1 cells (in parentheses).

^cR group is in meta position.